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Leßmann et al. present a chiral natural-product-derived library of a,b-unsaturated d-lactones
obtained through stereoselective synthesis on a solid support [1]. Phenotypic screening of this
compound collection provided new modulators of cell cycle progression and of viral cell entry with
high hit rates.In this issue of Chemistry & Biology,
Waldmann and colleagues report on
the discovery of new modulators of
cell cycle progression and viral entry
through cellular screening of a natu-
ral-product-derived compound library
[1]. This library was built around a
a,b-unsaturated d-lactone scaffold,
which is a frequently encountered
structural motif in biologically active
natural products (Figure 1). Screening
was conducted using fluorescence-
based cellular assays that scored for
effects on the actin or microtubule
cytoskeleton, or, in a second case, for
inhibition of cellular entry of the vesic-
ular stomatitis virus (VSV). Remarkably,
several compounds with activities in
the low mM concentration range could
be identified in both assay systems, in
spite of a library size of only 50 com-
pounds. Compared to conventional
HTS campaigns, this is a spectacular
hit rate. Two of the compounds that
scored positive in the cell cycle pro-gression assay were subsequently
demonstrated to inhibit tubulin poly-
merization in vitro, thus linking the
activity observed at the cellular level
to a specificmolecular target (although
other targets may still contribute to the
overall cellular phenotype).
Based on this short factual sum-
mary, the paper would appear to de-
scribe what nowadays might be called
a ‘‘typical’’ chemical biology project,
namely the screening of a library
of low-molecular-weight synthetic
compounds in fluorescence-based,
phenotypic cellular assays followed
(sometimes) by the analysis of hit com-
pounds in target-specific systems.
However, the paper is not just a ‘‘typi-
cal’’ (yet important) manifestation of
modern chemical biology research. It
is particularly notable for the concep-
tual framework that forms the basis
for library design and synthesis and
for Waldmann’s research in general
[2, 3]. The dissection of the overallChemistry & Biology 14, April 2007 ªconcept underlying Waldmann’s ap-
proach to the identification of new
tool compounds for chemical biology
research and new lead structures for
drug discovery reveals three essential
ingredients (apart from the use of
powerfulscreeningtechnology),whose
combination now has been demon-
strated repeatedly to enable the effi-
cient identification of potent and spe-
cific inhibitors of various biological
targets [2, 3].
The first of these ingredients is the
idea that natural products represent
prevalidated lead structures for chem-
ical biology and medicinal chemistry
research, due to an inherent propen-
sity for protein binding. In other words,
natural products are good starting
points for the discovery of ligands for
virtually any protein, as they have
evolved to do precisely this, bind to
proteins, either during their own bio-
synthesis or through their involvement
in the modulation of a vast array of2007 Elsevier Ltd All rights reserved 347
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course, this does not mean
that just any natural product
will bind to just any protein,
and even if this is the case,
the binding may often not
be strong or specific
enough to be practically
useful. However, what it
does mean is that the struc-
tures of natural products
can guide the design of
screening libraries with
a higher potential for hit
identification than simple
random compound collec-
tions. In order to provide
a systematic basis for the
implementation of this con-
cept, Waldmann and co-
workers have elaborated
a tree-like classification
system for natural products,
termed ‘‘SCONP’’ for struc-
tural classification of natural
products, which provides
a collection of possible
scaffolds for library design
[2]. One of these scaffolds
is a a,b-unsaturated d-lac-
tone ring and this is the
core structure of the library
investigated in the current
report [1].
The second essential ele-
ment of Waldmann’s ap-
proach to lead and tool
compound identification is
the idea that only a limited
number of binding site to-
pologies for small molecule
ligands exists across all
protein families, termed ‘‘ligand-sens-
ing cores of protein domains (PSSC)’’
[4]. As a consequence, compounds
binding to a given protein may be use-
ful as starting points for ligand identifi-
cation for another protein with similar
ligand binding site topology. Wald-
mann and coworkers have clearly
shown that the concept even holds
for proteins with different overall struc-
tural features, i.e., similarities in the li-
gand sensing cores can exist indepen-
dent of similarities in overall protein
folding topology [5]. Although the
screens discussed in Leßmann et al.
[1] are not directed toward individual
isolated targets, the concept of
PSSC’s was still an implicit part of
the library design process. For exam-
ple, a,b-unsaturated d-lactone rings
frequently occur in natural products
that are phosphatase inhibitors, which
are likely to play important roles in the
regulation of cell cycle progression
and viral entry. Thus, the current library
indeed had a significant a priori poten-
tial to provide hits for themodulation of
these cellular processes. The concept
of developing new lead structures
from existing ligands for other proteins
is not entirely new, but before Wald-
mann’s work these ideas were mostly
limited to proteins from the same tar-
get family (e.g., kinases) [6, 7]. Most
importantly, Waldmann’s
work on ligand binding site
similarity together with the
development of a natural
product classification sys-
tem for the first time has
provided a systematic con-
ceptual framework, which




The third essential ingre-
dient in themix is, of course,
the synthesis of appropriate
compound libraries. It is
self-evident that Wald-
mann’s approach requires
the screening of ‘‘custom-
made’’ structures and (for
the most part) cannot rely
on the use of commercially
available libraries. In a
most appropriate way,
Waldmann refers to the syn-
thesis of compound librar-
ies based on the premises
outlined above as ‘‘biology-
oriented synthesis’’, i.e.,
synthesis that is guided by
biology-derived structural
principles and the biological
characteristics of the sys-
tem to be investigated. He
also stresses in the paper
that the full exploitation of
biology-oriented synthesis
will require acomprehensive
set of methods for the enan-
tioselective construction of
screening libraries of ster-
eochemically homoge-
neous compounds, in particular on
solid-phase, and he correctly points
out that the corresponding methods
development, although not unex-
plored, still is an underdeveloped
area of research in organic chemistry.
The synthesis of the a-pyrone library
investigated in the current paper is
based on a highly enantioselective
catalytic oxa Diels-Alder reaction,
which was adapted to solid-phase
synthesis, but Waldmann’s group
has also developed stereoselective
methods for the elaboration of other
natural product scaffolds on solid-
phase (referenced in [1]). It is worth
noting at this point that the work
Figure 1. A Natural Product-Derived Structural Motif
as Template for New Cell Cycle Modulators and Inhibitors
of Viral Entry
The classification of overall natural product space leads to high-
frequency structural motifs, such as a,b-unsaturated d-lactones,
which provided the core structure for the enantioselective solid-phase
synthesis of a high-potential screening library. Phenotypic screening
identified several hit compounds interfering either with cell cycle
progression or viral cell entry. Two actives from the cell cycle progres-
sion screen were subsequently shown to be new inhibitors of tubulin
polymerization.348 Chemistry & Biology 14, April 2007 ª2007 Elsevier Ltd All rights reserved
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Previewspresented in Leßmann et al., in spite of
its success in identifying interesting
new modulators of cellular processes,
does not even fully exploit the power of
the synthetic methodology developed.
All library members screened exhibit
the R-configuration at C-6 of the
a-pyrone ring, whereas at least one
of the natural products shown in the
paper as examples of structures incor-
porating a a,b-unsaturated d-lactone
ring has an S-configuration at that
position.Obviously,S-configuredprod-
ucts are equally accessible by the
Diels-Alder methodology developed
as those with R-configuration.
Biology-oriented synthesis as de-
fined by Waldmann is not to be con-
fused with and has to be distinguished
from ‘‘diversity-oriented synthesis’’ or
DOS [8], which entails the synthesis of
large libraries of structurally complex
molecules in a minimum number of
steps. Based on their structural com-
plexity, the members of these DOS
libraries are meant to have ‘‘natural-
product-like’’ characteristics, but li-
brary design is not guided primarily by
the structural characteristics of realnatural products. Biology-oriented
and diversity-oriented syntheses
should be considered as complemen-
tary approaches toward the iden-
tification of biologically active mole-
cules in cellular or target-based
screening assays, each of which will
be found to have its own merits and
limitations.
In the current paper, the screening of
a library of only 50 compounds sufficed
to identify modulators of two unrelated
biological processes, cell cycle pro-
gression throughmitosis and viral entry
into host cells, with the majority of hits
not exhibiting any ‘‘cross-reactivity’’
between the two assays. In principle,
such compounds could also represent
structural entry points for the discovery
of new drugs, but, obviously, even in
the best of cases, this would require
a significant amount of optimization
work.Nevertheless, thepotential exists
and biology-oriented synthesis un-
doubtedly will deliver many more tool
compounds for chemical biology and
drug discovery research, and, in indi-
vidual cases, also lead structures for
medicinal chemistry.Chemistry & Biology 14, April 2007 ªREFERENCES
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